Retatrutide Weight Loss: What to Know — Rewind Anti-Aging of Miami
← Back to Blog
weight loss · 12 min read

Retatrutide Weight Loss: What to Know

Learn about retatrutide for weight loss, its triple-agonist mechanism, Phase 2 trial results showing up to 24.2% body weight reduction, and how it compares.

By the Rewind medical team
Medically reviewed by Alexia Padron, MSN, APRN, FNP-BC ·
Share:

Retatrutide has emerged as one of the most closely watched developments in medical weight loss. As the first triple hormone receptor agonist to reach advanced clinical trials, it represents a meaningful evolution beyond the dual-agonist and single-agonist therapies that have already transformed medical weight loss programs. In Eli Lilly’s trials, adults on the 12 mg dose lost an average of 24.2% of body weight in 48 weeks in Phase 2 and 28.3% in 80 weeks in the Phase 3 TRIUMPH-1 trial, where nearly half of that group lost at least 30% — outcomes in the range historically seen with bariatric surgery.

This guide covers everything you need to know about retatrutide: how it works, what the clinical evidence shows, how it compares to existing options, what side effects to expect, and whether it might be the right fit for your weight loss goals.

What Is Retatrutide?

Retatrutide is an investigational peptide therapy developed by Eli Lilly and Company. It belongs to a new class of medications known as triple hormone receptor agonists, meaning it simultaneously activates three distinct hormonal pathways involved in appetite regulation, blood sugar control, and energy metabolism.

Unlike semaglutide, which targets only the GLP-1 receptor, or tirzepatide, which targets GLP-1 and GIP, retatrutide activates all three: GLP-1, GIP, and the glucagon receptor. This triple mechanism addresses weight loss from complementary angles, combining appetite suppression with fat breakdown driven by the glucagon receptor.

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with the dosing schedule used by other incretin-based therapies.

How Retatrutide Works: The Triple Agonist Mechanism

Two clinicians study a volumetric torso render with the liver highlighted on a large wall display

Understanding retatrutide’s three receptor targets explains why this medication has generated such strong clinical interest.

GLP-1 Receptor Activation

Glucagon-like peptide-1 (GLP-1) is a gut hormone that signals satiety to the brain, slows gastric emptying to prolong feelings of fullness, and enhances glucose-dependent insulin secretion. GLP-1 receptor agonism is the foundation of both semaglutide and tirzepatide, and it remains central to retatrutide’s appetite-suppressing effects.

Research published in Physiological Reviews (2007) by Holst established GLP-1 as one of the most important regulators of post-meal satiety. By mimicking this hormone, retatrutide helps reduce hunger, decrease food intake, and improve blood sugar regulation.

GIP Receptor Activation

Glucose-dependent insulinotropic polypeptide (GIP) is the second incretin hormone targeted by retatrutide. While GIP’s role in weight management was historically debated, recent research has clarified its importance.

A study published in Cell Metabolism (2022) by Killion et al. demonstrated that GIP receptor activation in the central nervous system contributes to appetite suppression through pathways that complement, rather than duplicate, GLP-1 signaling. Additionally, GIP influences adipose tissue function and insulin sensitivity, potentially improving the body’s handling of dietary fat and reducing ectopic fat deposition.

The combination of GLP-1 and GIP activation is the same dual mechanism used by tirzepatide. What sets retatrutide apart is the addition of the third target.

Glucagon Receptor Activation: The Differentiator

The glucagon receptor is what makes retatrutide unique. Glucagon, produced by alpha cells in the pancreas, is traditionally known for raising blood sugar by stimulating the liver to release stored glucose. Including a glucose-raising hormone in a weight loss medication might seem paradoxical, but the metabolic rationale is sound.

Glucagon receptor activation produces several effects relevant to weight loss. It promotes hepatic fat oxidation, enhancing the liver’s ability to break down and use stored fat — in retatrutide’s Phase 2 liver substudy, a blood marker of fat burning rose two- to threefold and liver fat fell 82.4% in 24 weeks on 12 mg (Sanyal et al., Nature Medicine, 2024). In animal studies, it also added calorie burn on top of reduced food intake (Coskun et al., Cell Metabolism, 2022). And it contributes to satiety signaling, complementing the appetite-suppressing effects of GLP-1 and GIP.

The net effect is a medication that reduces how much you eat and adds a third pathway aimed at stored fat.

Retatrutide Clinical Trial Results

The Phase 2 Trial

The most significant data for retatrutide comes from a Phase 2 dose-finding trial published in the New England Journal of Medicine in July 2023. Led by Jastreboff et al., this randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher with at least one weight-related comorbidity).

Participants were randomized to receive one of several retatrutide dose levels (1 mg, 4 mg, 8 mg, or 12 mg) or placebo, administered as once-weekly subcutaneous injections over 48 weeks. All participants received standard lifestyle counseling.

The results were striking:

  • 1 mg dose: 8.7% average body weight loss
  • 4 mg dose: 17.1% average body weight loss
  • 8 mg dose: 22.8% average body weight loss
  • 12 mg dose: 24.2% average body weight loss
  • Placebo: 2.1% average body weight loss

At the highest dose, every participant in the 12 mg group lost at least 5% of their body weight, 93% lost at least 10%, and 83% lost at least 15% (placebo: 27%, 9% and 2%). Waist circumference fell by 19.6 cm.

Context: How This Compares

To appreciate the significance of these numbers, consider them alongside the landmark trials for existing medications:

MedicationTrialDurationAverage Weight Loss
Semaglutide 2.4 mgSTEP 168 weeks14.9%
Tirzepatide 15 mgSURMOUNT-172 weeks22.5%
Retatrutide 12 mgPhase 248 weeks24.2%

Retatrutide achieved 24.2% weight loss in 48 weeks, while tirzepatide reached 22.5% in 72 weeks, a notably longer treatment period. These are separate trials; the direct comparison, TRIUMPH-5, is still running.

The TRIUMPH Phase 3 Program

Eli Lilly has reported results from five Phase 3 trials, and the larger trials have confirmed and extended the Phase 2 result:

TrialPopulationDurationWeight Loss on 12 mgPlacebo
TRIUMPH-12,339 adults with obesity or overweight, no diabetes80 weeks28.3%2.2%
TRIUMPH-4445 adults with obesity and knee osteoarthritis68 weeks28.7%2.1%
TRIUMPH-31,949 adults with severe obesity and cardiovascular disease80 weeks22.6%3.2%
TRIUMPH-21,152 adults with type 2 diabetes80 weeks20.8%4.0%
TRANSCEND-T2D-1537 adults with type 2 diabetes40 weeks15.3%2.6%

In TRIUMPH-1, 45.3% of the 12 mg group lost at least 30% of their body weight and 65.3% reached a BMI under 30. Lilly plans to submit retatrutide for U.S. approval in the first quarter of 2027.

Retatrutide and Liver Health

Clinician scanning a man's liver with ultrasound in a bright clinic room

One particularly promising aspect of retatrutide’s profile is its benefit for liver health. The Phase 2 obesity trial included a substudy of 98 adults without diabetes who had at least 10% liver fat, and the results were notable.

Measured by MRI-proton density fat fraction (MRI-PDFF), liver fat fell 81.4% on 8 mg and 82.4% on 12 mg at 24 weeks, versus a 0.3% rise on placebo. On 12 mg, 86% of participants reached normal liver fat (under 5%), and fat around the organs fell by up to 48% at 48 weeks (Sanyal et al., Nature Medicine, 2024).

This finding is significant because NAFLD affects an estimated 25 to 30% of the global adult population and is a leading cause of liver disease progression. According to a review published in Hepatology (2023) by Rinella et al., effective pharmacological treatments for NAFLD remain limited, and retatrutide’s dual action of promoting hepatic fat oxidation through the glucagon pathway while reducing overall body weight could position it as a treatment for both obesity and fatty liver disease.

Side Effects and Safety Profile

Common Side Effects

The side effect profile of retatrutide in Phase 2 trials was consistent with other incretin-based therapies. The most commonly reported adverse events included nausea (reported in approximately 25 to 45% of participants depending on dose, typically mild and transient), diarrhea, constipation, vomiting, decreased appetite, and abdominal discomfort.

These gastrointestinal effects were most pronounced during dose escalation and generally improved as participants adjusted to each dose level. The gradual titration protocol used in the trial was specifically designed to minimize these effects.

Less Common Adverse Events

Heart rate rose in a dose-dependent way, peaked around week 24, and then declined; similar increases have been observed with other GLP-1 receptor agonists. Mild elevations in liver enzymes were noted in a small number of participants, though the clinical significance of these changes is still being evaluated. Gallbladder-related events, including gallstones, were reported at rates consistent with rapid weight loss from any cause.

Safety Considerations Specific to the Glucagon Component

The inclusion of glucagon receptor activation raises specific pharmacological considerations. Because glucagon promotes hepatic glucose output, there is a theoretical concern about hyperglycemia, particularly in patients with diabetes. However, the Phase 2 trial data showed that the GLP-1 and GIP components effectively counterbalanced any glucose-raising effect of the glucagon component, resulting in net improvements in glycemic control.

A 2023 review published in Nature Reviews Endocrinology by Muller et al. noted that the balance between glucagon’s catabolic effects and the anabolic effects of GLP-1 and GIP appears to be well-calibrated in retatrutide’s molecular design, though long-term safety monitoring will be critical.

Important Warnings

Consistent with other incretin-based therapies, the precautions that apply to retatrutide include pancreatitis and the thyroid C-cell tumors observed in rodent studies of this drug class. Retatrutide’s trials excluded people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and it should not be used in those patients. Pregnant or breastfeeding women should not use this medication.

Who Is a Good Candidate for Retatrutide?

Based on the trial results and the medication’s mechanism of action, candidates who may benefit most from retatrutide include patients with significant weight to lose who are seeking the most potent pharmacological option, individuals with co-existing non-alcoholic fatty liver disease given retatrutide’s hepatic benefits, patients with type 2 diabetes or insulin resistance who want combined metabolic and weight management benefits, and those interested in a medication that adds a fat-burning liver pathway to appetite suppression.

Who Should Not Use Retatrutide

Retatrutide is not appropriate for individuals with a history of medullary thyroid carcinoma or MEN 2, those with active or recent pancreatitis, pregnant or breastfeeding women, individuals under 18, or anyone with a history of serious hypersensitivity to incretin-based medications.

What to Expect During Treatment

Physician and patient talking across a walnut desk

Dose Titration

Like other incretin-based therapies, retatrutide follows a structured dose-escalation protocol. In the Phase 2 trial, treatment began at low doses with increases every four weeks to allow the body to adjust. Patients should expect the most noticeable side effects during the first one to two weeks at each new dose level, with symptoms typically subsiding as tolerance develops.

Timeline of Results

Based on Phase 2 trial data, most patients can expect the following general progression: during weeks one through four, noticeable appetite suppression and early changes in eating behavior begin. By weeks four through twelve, measurable weight loss becomes apparent, typically 3 to 8% of body weight. From weeks twelve through twenty-four, weight loss accelerates as the dose reaches therapeutic levels, with most patients achieving 10 to 18% reduction. Between weeks twenty-four and forty-eight, weight loss continues, with the 12 mg group averaging 24.2% at week 48; in the 80-week Phase 3 TRIUMPH-1 trial, the 12 mg average reached 28.3%.

Lifestyle Integration

The most successful outcomes in clinical trials involved participants who combined retatrutide with structured lifestyle modifications. Key strategies include consuming adequate protein (at least 1.2 to 1.6 grams per kilogram of body weight daily) to preserve lean muscle mass, engaging in resistance training two to three times weekly, maintaining hydration, prioritizing sleep, and attending regular medical follow-up for monitoring and dose optimization.

A 2023 consensus statement published in Obesity by the Obesity Medicine Association emphasized that anti-obesity medications produce the most durable results when integrated with peptide therapy programs that include behavioral and lifestyle interventions rather than used as standalone treatments.

The Bigger Picture: Where Retatrutide Fits

Retatrutide represents the cutting edge of a broader trend in metabolic medicine: the development of multi-receptor agonists that address obesity through complementary mechanisms. According to a 2024 review in Nature Reviews Drug Discovery, the progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) therapies mirrors a growing understanding that obesity is a complex, multi-hormonal condition that benefits from multi-target pharmacological intervention.

With Phase 3 trials now confirming the Phase 2 findings, retatrutide is positioned to offer weight loss outcomes in the range of surgical intervention without the associated surgical risks.

However, it is important to maintain perspective. The most effective weight loss treatment is the one that works for your individual biology, fits your health profile, and can be maintained consistently over time. Not every patient needs the most potent available option, and the right choice depends on a thorough clinical evaluation.

How Rewind Anti-Aging of Miami Can Help

Navigating the rapidly evolving landscape of medical weight loss requires expertise and personalized guidance. At Rewind Anti-Aging of Miami, we specialize in peptide-based weight management programs that match the right therapy to the right patient.

Our comprehensive approach includes thorough metabolic and hormonal evaluation to establish your baseline health profile, individualized treatment selection based on your weight loss goals, health history, and medication tolerance, access to current and emerging peptide therapies with medical supervision, structured dose titration and ongoing monitoring including regular lab work and body composition assessments, nutritional planning with emphasis on protein optimization to preserve lean muscle mass, and exercise guidance to enhance fat loss and support long-term metabolic health.

Whether retatrutide, tirzepatide, semaglutide, or another approach is the right fit, our team provides the clinical expertise and ongoing support you need for sustainable results. Book a consultation today to discuss your weight loss goals and explore which treatment options align with your health profile.


Interested in advanced weight loss therapy? Rewind Anti-Aging of Miami offers personalized weight loss therapy with access to the latest peptide therapy options and comprehensive medical support. Schedule a consultation →

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Clinical trial results may not reflect individual outcomes. Always consult with a qualified healthcare provider before starting any new medication or treatment program.

Frequently Asked Questions

How much weight can you lose with retatrutide?

In Phase 2 clinical trials, participants receiving the highest dose of retatrutide (12 mg) lost an average of 24.2% of their body weight over 48 weeks. In the Phase 3 TRIUMPH-1 trial, the 12 mg average was 28.3% at 80 weeks, and 45% of that group lost more than 30%. Individual results vary based on dosage, lifestyle factors, and baseline health status.

Is retatrutide FDA approved?

Not yet. Eli Lilly has reported results from five Phase 3 trials (the TRIUMPH program and TRANSCEND-T2D-1) and plans to submit retatrutide for U.S. approval in the first quarter of 2027.

How does retatrutide compare to semaglutide and tirzepatide?

Retatrutide targets three hormone receptors (GLP-1, GIP, glucagon) compared to semaglutide's one (GLP-1) and tirzepatide's two (GLP-1, GIP). Retatrutide produced 24.2% weight loss at 48 weeks in Phase 2 and 28.3% at 80 weeks in Phase 3, compared with tirzepatide's 22.5% at 72 weeks and semaglutide's 14.9% at 68 weeks in their own trials. A head-to-head trial against tirzepatide, TRIUMPH-5, is still running.

What are the side effects of retatrutide?

Common side effects include nausea, diarrhea, constipation, vomiting, and decreased appetite, similar to other incretin-based therapies. Heart rate rose in a dose-dependent way, peaking around week 24 and then declining, and some participants had mild increases in liver enzymes. Gallbladder events were also reported, consistent with rapid weight loss. Side effects are typically managed through gradual dose escalation.

How does retatrutide work differently from other weight loss medications?

Retatrutide is unique as the first triple agonist to reach advanced clinical trials. By activating the glucagon receptor in addition to GLP-1 and GIP, it promotes fat oxidation, especially in the liver, rather than relying solely on appetite suppression. In a Phase 2 substudy, liver fat fell 82% in 24 weeks on the 12 mg dose.

Who is a good candidate for retatrutide?

Retatrutide may be appropriate for adults with weight to lose, particularly those seeking the largest average weight loss seen in trials so far. Candidates should be evaluated by a healthcare provider who can assess their full medical history and determine whether this therapy is appropriate.

More in weight loss

⚕ Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All treatments at Rewind Anti-Aging of Miami are performed under the supervision of licensed medical professionals. Individual results may vary. Consult your physician before beginning any new treatment protocol.

Meet our clinical team →

Not sure which treatment is right for you?

Take our free 2-minute assessment and get a personalized recommendation.

Take the Quiz →

Take the Next Step

Our team at Rewind Anti-Aging in Miami is here to help you determine if medical weight loss is right for your goals.

Chat with Rewind AI

We typically reply instantly

Book
Powered by AI — not medical advice
Book Consultation